Issues in clinical trial design for tumor marker studies

Daniel Sargent, Carmen Allegra

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Scientific inquiry into the discovery, development, and application of tumor markers is proceeding rapidly. Despite this explosion in research and interest, the design of studies to formally assess the value of tumor markers in clinical practice is inconsistent and immature. Indeed, few markers have been widely accepted into standard clinical practice. Many issues must be prospectively considered in a methodical, systematic, and scientific fashion if progress is to be made in the development of validated tests that will have value in the management of patients with cancer. The purpose of this report is to present a discussion of the issues involved in designing clinical studies of putative tumor markers which provide sufficient data to result in the incorporation of the marker into clinical practice. We will focus on the design of studies to demonstrate and validate the clinical utility of both prognostic and predictive markers. Topics to be covered include issues of patient and sample heterogeneity, the prevalence of the marker, the sample capture rate, and the choice of endpoints. This will be followed by explicit consideration of study design, specifically the trial randomization schema for both prognostic and predictive factor studies.

Original languageEnglish (US)
Pages (from-to)222-230
Number of pages9
JournalSeminars in Oncology
Volume29
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Tumor Biomarkers
Clinical Trials
Explosions
Random Allocation
Research Design
Biomarkers
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Issues in clinical trial design for tumor marker studies. / Sargent, Daniel; Allegra, Carmen.

In: Seminars in Oncology, Vol. 29, No. 3, 2002, p. 222-230.

Research output: Contribution to journalArticle

Sargent, Daniel ; Allegra, Carmen. / Issues in clinical trial design for tumor marker studies. In: Seminars in Oncology. 2002 ; Vol. 29, No. 3. pp. 222-230.
@article{6d05c223c9384c15b74d06c170db7500,
title = "Issues in clinical trial design for tumor marker studies",
abstract = "Scientific inquiry into the discovery, development, and application of tumor markers is proceeding rapidly. Despite this explosion in research and interest, the design of studies to formally assess the value of tumor markers in clinical practice is inconsistent and immature. Indeed, few markers have been widely accepted into standard clinical practice. Many issues must be prospectively considered in a methodical, systematic, and scientific fashion if progress is to be made in the development of validated tests that will have value in the management of patients with cancer. The purpose of this report is to present a discussion of the issues involved in designing clinical studies of putative tumor markers which provide sufficient data to result in the incorporation of the marker into clinical practice. We will focus on the design of studies to demonstrate and validate the clinical utility of both prognostic and predictive markers. Topics to be covered include issues of patient and sample heterogeneity, the prevalence of the marker, the sample capture rate, and the choice of endpoints. This will be followed by explicit consideration of study design, specifically the trial randomization schema for both prognostic and predictive factor studies.",
author = "Daniel Sargent and Carmen Allegra",
year = "2002",
doi = "10.1053/sonc.2002.32898",
language = "English (US)",
volume = "29",
pages = "222--230",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Issues in clinical trial design for tumor marker studies

AU - Sargent, Daniel

AU - Allegra, Carmen

PY - 2002

Y1 - 2002

N2 - Scientific inquiry into the discovery, development, and application of tumor markers is proceeding rapidly. Despite this explosion in research and interest, the design of studies to formally assess the value of tumor markers in clinical practice is inconsistent and immature. Indeed, few markers have been widely accepted into standard clinical practice. Many issues must be prospectively considered in a methodical, systematic, and scientific fashion if progress is to be made in the development of validated tests that will have value in the management of patients with cancer. The purpose of this report is to present a discussion of the issues involved in designing clinical studies of putative tumor markers which provide sufficient data to result in the incorporation of the marker into clinical practice. We will focus on the design of studies to demonstrate and validate the clinical utility of both prognostic and predictive markers. Topics to be covered include issues of patient and sample heterogeneity, the prevalence of the marker, the sample capture rate, and the choice of endpoints. This will be followed by explicit consideration of study design, specifically the trial randomization schema for both prognostic and predictive factor studies.

AB - Scientific inquiry into the discovery, development, and application of tumor markers is proceeding rapidly. Despite this explosion in research and interest, the design of studies to formally assess the value of tumor markers in clinical practice is inconsistent and immature. Indeed, few markers have been widely accepted into standard clinical practice. Many issues must be prospectively considered in a methodical, systematic, and scientific fashion if progress is to be made in the development of validated tests that will have value in the management of patients with cancer. The purpose of this report is to present a discussion of the issues involved in designing clinical studies of putative tumor markers which provide sufficient data to result in the incorporation of the marker into clinical practice. We will focus on the design of studies to demonstrate and validate the clinical utility of both prognostic and predictive markers. Topics to be covered include issues of patient and sample heterogeneity, the prevalence of the marker, the sample capture rate, and the choice of endpoints. This will be followed by explicit consideration of study design, specifically the trial randomization schema for both prognostic and predictive factor studies.

UR - http://www.scopus.com/inward/record.url?scp=0036269892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036269892&partnerID=8YFLogxK

U2 - 10.1053/sonc.2002.32898

DO - 10.1053/sonc.2002.32898

M3 - Article

C2 - 12063675

AN - SCOPUS:0036269892

VL - 29

SP - 222

EP - 230

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3

ER -